Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Amphastar P(AMPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AMPH
10/02/2026: AMPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Amphastar Pharmaceuticals is a specialized biopharmaceutical company focused on complex injectable and inhalation products. It has built a reputation for technical manufacturing proficiency, which provides a competitive barrier in the generic and niche drug markets. The company's recent acquisition of the Baqsimi franchise represents a strategic shift toward higher-margin, branded offerings, fueling its primary growth narrative. However, risks include regulatory uncertainty, significant competition in the generic sector, and the complexities of scaling newly acquired assets. Amphastar may be suitable for growth-oriented investors, though they must monitor FDA approval pipelines and integration performance carefully, as the stock offers no dividend income.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company provides exposure to product portfolio expansion and strategic market acquisition in specialized segments. |
| Momentum investor | Mixed fit | Momentum can be volatile based on specific FDA approval timelines and earnings beats. |
| Value investor | Mixed fit | Valuation fluctuates significantly based on the success of new product commercialization. |
| Dividend investor | Weak fit | The company does not pay a dividend, focusing instead on capital reinvestment. |
| Low-risk investor | Weak fit | The pharmaceutical sector, especially for smaller-cap players, involves significant regulatory and clinical trial risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp moves based on clinical data, regulatory rulings, and quarterly earnings performance. |
| Valuation risk | Medium | Market expectations for growth must be met to sustain premium trading multiples. |
| Competition risk | Medium / high | Aggressive pricing from large generic competitors can erode margins on staple products. |
| Business quality | Medium | Vertical integration provides a competitive edge, though execution on large acquisitions is key. |
| Dividend income | Low / none | Investors seeking immediate cash yield will not find it here. |
| Execution risk | Medium | Success depends heavily on the effective commercialization of recent acquisitions like Baqsimi. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -53.12% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio 15 | 1Y Target Price 22.5 |
Price to earnings Ratio 15 | 1Y Target Price 22.5 | ||
Volume (30-day avg) 483.9K shares | Beta 0.92 | 52 Weeks Range 16.64 - 29.52 | Updated Date 10/02/2026 |
52 Weeks Range 16.64 - 29.52 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.69 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Injectables | Generic and proprietary sterile, parenteral drugs for hospitals. | The bread-and-butter revenue driver for the company. |
| Inhalation/Intranasal | Complex delivery systems like Baqsimi and Primatene Mist. | High-growth segment with strong proprietary assets. |
| Geographic Exposure | US-focused commercial market with manufacturing globally. | Revenue is heavily tied to the US healthcare system and pricing. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 15 | Forward PE - | Enterprise Value 1.46B | Price to Sales(TTM) 1.48 |
Enterprise Value 1.46B | Price to Sales(TTM) 1.48 | ||
Enterprise Value to Revenue 2 | Enterprise Value to EBITDA 7.57 | Shares Outstanding 42.54M | Shares Floating 31.29M |
Shares Outstanding 42.54M | Shares Floating 31.29M | ||
Percent Insiders 30.81 | Percent Institutions 68.71 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Amphastar P
Exchange NASDAQ | Headquarters Rancho Cucamonga, CA, United States | ||
IPO Launch date 2014-06-25 | Co-Founder, President, CEO, Chief Scientific Officer & Director Dr. Yongfeng Zhang Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1976 | Website https://www.amphastar.com |
Full time employees 1976 | Website https://www.amphastar.com | ||
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.